



**Proteomics International**

LABORATORIES LTD

**ASX Release  
5 March 2018**

**ASX code: PIQ**

## **Secondary Trading Notice**

Proteomics International Laboratories Ltd (Proteomics International, ASX: PIQ) has today issued 3,868,305 fully paid ordinary shares in the capital of the Company to acquire 10% of the fully diluted issued share capital of CPR Pharma Services Pty Ltd. A voluntary escrow period of 12 months applies to the Shares. This is in accordance with the announcement to the market on 2 February 2018.

The Company has issued the Shares using its 15% placement capacity.

### **Secondary Trading Notice Pursuant to Paragraph 708A(5)(e) of the Corporations Act 2001 ("Act")**

The Act restricts the on-sale of securities issued without disclosure, unless the sale is exempt under section 708 or 708A of the Act. By giving this notice, a sale of the Shares noted above will fall within the exemption in section 708A(5) of the Act.

The Company hereby notifies ASX under paragraph 708A(5)(e) of the Act that:

- (a) the Company issued the Shares without disclosure to investors under Part 6D.2 of the Act;
- (b) as at the date of this Notice, the Company has complied with the provisions of Chapter 2M of the Act as they apply to the Company, and section 674 of the Act; and
- (c) as at the date of this Notice, there is no information:
  - (i) that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules; and
  - (ii) that investors and their professional advisers would reasonably require for the purposes of making an informed assessment of:
    - a. the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
    - b. the rights and liabilities attaching to the relevant Shares.

Proteomics International remains engaged with a number of potential strategic partners to bring the Promarker™ technology to market in Australia and overseas. The Company is also finalising negotiations with potential underwriters of the PIQO options to take any shortfall that may arise after the expiry date of 31 March 2018. It is possible that announcements may be made in the foreseeable future which could influence the price of PIQ shares and options.

ENDS

### **For further information please contact:**

Karen Logan  
Company Secretary  
Proteomics International Laboratories Ltd  
T: +61 8 9389 1992  
E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com)  
[www.proteomicsinternational.com](http://www.proteomicsinternational.com)

**Proteomics International Laboratories Ltd**

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)